Pernix therapeutics holdings, inc. (PTX)
Income statement / Yearly
Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10
Net revenues

146,068

140,856

175,850

121,747

84,872

61,313

60,606

-

Costs and operating expenses:
Net revenues

-

-

-

-

-

-

-

33,227

Cost of product sales

44,631

43,320

51,408

47,965

43,870

23,377

20,921

5,442

Selling, general and administrative expense

76,801

98,834

97,421

60,158

62,551

35,452

22,157

15,188

Research and development expense

787

6,079

8,229

3,938

4,798

732

922

998

Loss on sale of PML (including impairment charge)

-

-

-

6,659

0

0

-

-

Loss from the operations of the joint venture with SEEK

-

-

-

-

-

-

-

0

Royalties expense, net

-

-

-

-

-

-

-

738

Depreciation and amortization expense

73,216

86,138

94,695

32,999

8,676

3,201

2,302

1,238

Change in fair value of contingent consideration

-1,045

-11,652

-138

0

-805

-

-

-

Loss from operations of the joint venture

-

-

-

-

-

-240

-814

-

Loss from disposal and impairments of assets

18,525

56,178

24,352

242

19,638

0

380

-

Gain from legal settlement

10,476

0

-

-

-

-

-

-

Restructuring costs

88

2,287

1,137

0

0

-

-

-

Total costs and operating expenses

202,527

281,184

277,104

151,961

138,728

63,002

47,498

23,607

Income (loss) from operations

-56,459

-140,328

-101,254

-30,214

-53,856

-1,689

13,107

9,620

Other income (expense):
Interest expense

36,957

37,857

-

-

-

-

-

-

Gain on sale of assets

2,000

0

-

-

-

-

-

-

Interest income

-

-

157

353

134

-

-

-

Interest expense

-

-

38,277

19,150

4,183

-

-

-

Change in fair value of derivative liability

47

8,935

19,315

0

0

-

-

-

Gain from exchange of debt

14,650

0

-

-

-

-

-

-

Foreign currency transaction gain

-49

99

-582

0

0

-

-

-

Change in fair value of put right

-

-

-

0

-8,361

0

0

-

Change in fair value of contingent consideration

-

-

-

-

-

0

0

-

Gain on contingent consideration and put right

-

-

-

0

16,269

0

0

-

Other income

-

-

-

-

-

-

-

286

Gain from bargain purchase

-

-

-

-

-

-

-

881

Interest expense, net

-

-

-

-

-

-95

-171

5

Gain on sale of investment

-

-

-

0

3,605

0

0

-

Cost of inducement

-

-

-19,500

0

0

-

-

-

Loss on extinguishment of debt

-

-

-1,112

0

0

-

-

-

Total other expense, net

-20,309

-28,823

-39,999

-18,797

7,464

-95

-171

-

Income (loss) before income tax expense

-76,768

-169,151

-141,253

-49,011

-46,392

-1,784

12,936

-

Total other income, net

-

-

-

-

-

-

-

1,174

Income (loss) before income taxes

-

-

-

-

-

-

-

10,794

Income tax expense

373

439

7,062

-13,725

-20,757

-374

4,589

1,486

Net income (loss) attributable to common stockholders

-77,141

-169,590

-148,315

-35,286

-25,635

-1,410

8,347

9,308

Net income (loss) per common share attributable to common stockholders:
Unrealized Gain (loss) during period, net of tax of $0 and $0, respectively

79

-79

0

0

-702

1,886

1,089

-

Reclassification adjustment for net gains included in net loss, net of tax of $0, $0 and ($1,332), respectively

-

-

-

0

2,273

0

0

-

Comprehensive loss

-77,062

-169,669

-148,315

-35,286

-28,610

476

9,436

9,308

Basic

-7.21

-21.67

-27.81

-0.93

-0.70

-0.05

0.35

0.40

Diluted

-7.21

-21.67

-27.81

-0.93

-0.70

-0.05

0.34

0.40

Weighted-average common shares outstanding:
Basic

10,706

7,827

5,333

37,871

36,444

28

23,990

23,415

Diluted

10,706

7,827

5,333

37,871

36,444

28

24,460

23,418